BENGALURU (Rueters): Gilead Sciences Inc said on Tuesday (May 5) it was in discussions with chemical and drug manufacturers to produce its experimental Covid-19 drug remdesivir for Europe, Asia and the developing world through at least 2022.
The drugmaker did not disclose details about the companies.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
